Posted by Michael Wonder on 21 May 2024
Transposon receives US FDA fast track designation for TPN-101 for progressive supranuclear palsy
21 May 2024 - TPN-101 is the first PSP treatment to reduce NfL and IL-6 levels, key biomarkers of neurodegeneration and neuroinflammation in progressive supranuclear palsy.
Transposon Therapeutics today announced that the US FDA has granted fast track designation to TPN-101 for progressive supranuclear palsy.
